Description

Microarray Panel:Common cancers (1) No. of samples59No. of patients59Core diameter2.0 mmFormat:Formalin FixedSection thickness 4 micrometer Core# No. Age Sex Organ Diagnosis pTNM Stage MAN2# Tissuetype Image 1 56 M Stomach adenocarcinoma, poorly differentiated T3N0M0 II 101 6 " class="fd_image"> 2 52 M Stomach adenocarcinoma, poorly differentiated T3N1M0 IIIA 102 6 " class="fd_image"> 3 39 M Stomach adenocarcinoma, poorly differentiated T3N2M0 IIIB 103 6 " class="fd_image"> 4 44 M Stomach adenocarcinoma, poorly differentiated T3N3M0 IV 104 6 " class="fd_image"> 5 65 F Stomach mucinous adenocarcinoma T3N1M0 IIIA 105 6 " class="fd_image"> 6 52 M Stomach adenocarcinoma, moderately differentiated T3N1M0 IIIA 106 6 " class="fd_image"> 7 66 M Stomach adenocarcinoma, poorly differentiated T3N2M0 IIIB 107 6 " class="fd_image"> 8 61 M Stomach adenocarcinoma, poorly differentiated T3N1M0 IIIA 108 6 " class="fd_image"> 9 39 F Stomach signet ring cell carcinoma T3N0M0 II 109 6 " class="fd_image"> 10 60 F Stomach adenocarcinoma, moderately differentiated T3N1M0 IIIA 110 6 " class="fd_image"> 11 64 F Esophagus adenocarcinoma, poorly differentiated T3N0M0 IIA 111 6 " class="fd_image"> 12 60 M Esophagus squamous cell carcinoma, well differentiated T3N1M0 III 112 6 " class="fd_image"> 13 73 M Esophagus squamous cell carcinoma, well differentiated T3N1M0 III 113 6 " class="fd_image"> 14 52 F Esophagus squamous cell carcinoma, well differentiated T3N1M0 III 114 6 " class="fd_image"> 15 77 M Esophagus squamous cell carcinoma, well differentiated T3N0M0 IIA 115 6 " class="fd_image"> 16 63 M Esophagus squamous cell carcinoma, well differentiated T3N1M0 III 116 6 " class="fd_image"> 17 47 M Esophagus squamous cell carcinoma, well differentiated T2N1M0 IIB 117 6 " class="fd_image"> 18 58 M Esophagus basaloid squamous cell carcinoma T3N0M0 IIA 118 6 " class="fd_image"> 19 60 F Esophagus squamous cell carcinoma, well differentiated T3N0M0 IIA 119 6 " class="fd_image"> 20 69 M Esophagus squamous cell carcinoma, well differentiated T3N0M0 IIA 120 6 " class="fd_image"> 21 69 M Lung adenocarcinoma, well differentiated T2N0M0 I B 121 6 " class="fd_image"> 22 71 M Lung large cell carcinoma T2N0M0 I B 122 6 " class="fd_image"> 23 65 M Lung squamous cell carcinoma, moderately differentiated T2N0M0 I B 123 6 " class="fd_image"> 24 62 M Lung squamous cell carcinoma, moderately differentiated T2N1M0 IIB 124 6 " class="fd_image"> 25 69 M Lung squamous cell carcinoma, moderately differentiated T4N0M0 IIIB 125 6 " class="fd_image"> 26 58 M Lung adenocarcinoma, well differentiated T2N0M0 I B 126 6 " class="fd_image"> 27 58 M Lung squamous cell carcinoma, moderately differentiated T2N1M0 IIB 127 6 " class="fd_image"> 28 61 M Lung squamous cell carcinoma, moderately differentiated T3N2M0 IIIA 128 6 " class="fd_image"> 29 52 M Lung squamous cell carcinoma, well differentiated T2N1M0 IIB 129 6 " class="fd_image"> 30 56 M Lung squamous cell carcinoma, well differentiated T2N0M0 IB 130 6 " class="fd_image"> 31 66 M Sigmoid colon adenocarcinoma, well differentiated T3N0M0 IIA 131 6 " class="fd_image"> 32 50 M Rectum adenocarcinoma, moderately differentiated T3N0M0 IIA 132 6 " class="fd_image"> 33 40 M Cecum adenocarcinoma, moderately differentiated T3N0M0 IIA 133 6 " class="fd_image"> 34 45 M Ascending colon adenocarcinoma, well differentiated T3N0M0 IIA 134 6 " class="fd_image"> 35 43 F Rectum mucinous adenocarcinoma T3N2M0 IIIC 135 6 " class="fd_image"> 36 44 F Ascending colon adenocarcinoma, moderately differentiated T3N1M0 IIIA 136 6 " class="fd_image"> 37 52 F Rectum adenocarcinoma, moderately differentiated T3N0M0 IIA 137 6 " class="fd_image"> 38 49 M Ascending colon adenocarcinoma, moderately differentiated T3N1M0 IIIA 138 6 " class="fd_image"> 39 61 F Rectum adenocarcinoma, moderately differentiated T3N1M0 IIIA 139 6 " class="fd_image"> 40 52 F Rectum adenocarcinoma, moderately differentiated T2N0M0 I 140 6 " class="fd_image"> 41 29 F Thyroid papillary carcinoma T2N0M0 I . 6 " class="fd_image"> 42 20 F Thyroid papillary carcinoma T2N0M0 I 142 6 " class="fd_image"> 43 15 F Thyroid papillary carcinoma T2N0M0 I 143 6 " class="fd_image"> 44 60 F Thyroid papillary carcinoma T2N0M0 II 144 6 " class="fd_image"> 45 47 F Thyroid papillary carcinoma T2N0M0 II 145 6 " class="fd_image"> 46 48 F Thyroid papillary carcinoma T3N1aM0 III 146 6 " class="fd_image"> 47 43 F Thyroid papillary carcinoma T1N0M0 I 147 6 " class="fd_image"> 48 56 F Thyroid papillary carcinoma T2N1bM0 IVA 148 6 " class="fd_image"> 49 55 F Thyroid papillary carcinoma T3N0M0 III 149 6 " class="fd_image"> 50 34 F Thyroid papillary carcinoma T3N0M0 I 150 6 " class="fd_image"> 51 57 F Kidney renal cell carcinoma, clear cell type T1aN0M0 I 151 6 " class="fd_image"> 52 50 F Kidney renal cell carcinoma, clear cell type T2N0M0 II 152 6 " class="fd_image"> 53 27 M Kidney nephrogenic carcinoma T2N0M0 II 153 6 " class="fd_image"> 54 56 M Kidney renal cell carcinoma, clear cell type T1aN0M0 I 154 6 " class="fd_image"> 55 47 M Kidney renal cell carcinoma, granular cell type T2N0M0 II 155 6 " class="fd_image"> 56 63 M Kidney renal cell carcinoma T2N0M0 II 156 6 " class="fd_image"> 57 53 M Kidney renal cell carcinoma, clear cell type T3aN0M0 III 157 6 " class="fd_image"> 58 62 M Kidney renal cell carcinoma, clear cell type T2N0M0 II 158 6 " class="fd_image"> 59 67 F Kidney renal cell carcinoma, clear cell type T3aN0M0 III . 6 " class="fd_image"> 60 . . Carbon . . . . .

Publications

ReadPublication using NBP2-30262.

Novus Biologicals北京代理，Novus Biologicals中国代理，Novus Biologicals上海代理，Novus Biologicals公司，Novus Biologicals 【详细说明】  Novus Biologicals北京代理，Novus Biologicals中国代理，Novus Biologicals上海代理，Novus Biologicals公司，Novus Biologicals 上海普迈生物科技有限公司签约代理      欢迎下载下面的资料以了解此产品的相关信息！预询产品订购信息  上海普迈生物致力于提供zui高质量的产品和服务组织形态学研究与竞争力的产品 产品和服务,有相关产品的问题请直接 期货每周下午5点前发定单，正常到上海时间为3-4周 现市区2天内送到，外地以快递为准 敬请关注！ ：   :www.pumaibio.com :pumaibio :（直接客户） （经销商） 促销etonbio、polysciences、Mattek、trevigen、Chromogenix、cyguns、IrvineScientific、Innovative Cell Technologies、enzo、novus、immunochemistry、eylabs、Polyplus、NIBSC、ALZET、hitobiotec、sutter instrument、mirus、StressMarq、Avanti、jena bioscience、Neuro Probe、tedpella、avanti、Rockland、CAYMAN、transgenomic、BioLegend、ambion、omicronbio、 Assaybiotech、chondrex、lc?laboratories、cosmobio、megazyme、NeoMarkers、BTI、eylabs、berryassoc、cellagentech、TOCRIS、Relia Tech、SouthernBiotech、Biosearch technology、Lumiprobe、StemCells?Inc、biovendor、NORGEN、alomone、jena?bioscience、Gracebio、Eurogentec、Gelcompany?、invitrogen、gene?bridges、MRC-Holland、laysanbio